Failure To Invest In Drug Repositioning Is Frustrating, Says EU Rare Disease Patients Group
Executive Summary
Yann Le Cam, who heads the EU network of rare disease patient organizations, is calling for innovative solutions to support the 'repositioning' of existing and new medicines that could potentially treat orphan conditions but are not developed by companies due to business considerations.
You may also be interested in...
Industry Welcomes Mandatory EU Joint Clinical Assessments For HTA
Draft proposals to improve EU-wide cooperation on health technology assessments, including mandatory joint clinical assessments, have won support from EFPIA, the European Federation of Pharmaceutical Industries and Associations.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.